Royalty Pharma plc (RPRX) Institutional Ownership

Ownership Summary

A total of 480 institutions have reported a stake in Royalty Pharma plc (NASDAQ:RPRX) as of September 2025, according to recent 13F filings with the SEC.

• The percentage of Royalty Pharma owned by institutions changed from 60.8% in June 2025 to 56.2% in September 2025, marking a slight down trend.
• Institutional share ownership changed by -1.96% QoQ, while the number of institutional owners saw an increase of 23.08% YoY.
• During the quarter, 270 institutions bought more Royalty Pharma shares, 155 sold shares, and 55 of the 480 total investors held their position steady.
• The aggregate institutional position in Royalty Pharma now stands at 327.80Mn shares as of September 2025, after investors decreased their holdings (down by 6.56Mn shares quarter on quarter which is up 17.59Mn shares year over year).
• MORGAN STANLEY's holding of 44.16Mn shares as of September 30, 2025 makes it the primary institutional investor in Royalty Pharma, owning 7.57% of the stock.
• Among the most significant buyers of Royalty Pharma during September 2025 were ADAGE CAPITAL PARTNERS GP, L.L.C. (5.97Mn), Capital International Investors (5.33Mn), Dorsey Asset Management, LLC (2.35Mn), JANE STREET GROUP, LLC (2.31Mn), Qube Research & Technologies Ltd (2.19Mn).
• Leading sellers of Royalty Pharma stock in September 2025 included VANGUARD GROUP INC (25.44Mn), FMR LLC (12.37Mn), MORGAN STANLEY (2.44Mn), CITADEL ADVISORS LLC (1.67Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (947.06K).
• The top 10 institutional holders of Royalty Pharma for the quarter ending September 2025 included MORGAN STANLEY (44.16Mn), FMR LLC (27.99Mn), Capital International Investors (27.21Mn), BlackRock, Inc. (26.20Mn), BAILLIE GIFFORD & CO (17.37Mn), Swedbank AB (12.20Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (11.97Mn), VANGUARD GROUP INC (10.94Mn), STATE STREET CORP (10.27Mn), GEODE CAPITAL MANAGEMENT, LLC (7.62Mn).